NCTimes.com Blogs

Amidst all the financial chaos of the Wall Street meltdown, Invitrogen Corp. closed the $2.65 billion financing needed to complete its purchase of Applied Biosystems, announced in June.

Carlsbad-based Invitrogen says the financing was “in line with expected terms.”

The combined company, to be headquartered in Carlsbad and named Applied Biosystems, will have as its chairman and CEO Greg Lucier, who’s now Invitrogen’s chairman and CEO.  The new Applied Biosystems expected to be an even more formidable competitor in supplying biotech and biological research products and tools.

Here’s my story on the merger announcement.

Shares of Acadia Pharmaceuticals jumped more than 16 percent this morning, with shares just before 9 a.m. up nearly 14 percent, at $3.03 per share.

San Diego-based Acadia announced today it has filed a registration statement for its capital infusion from Kingsbridge Capital Limited.

From the press release:

Under the terms of the CEFF, ACADIA has access, at its discretion, to up to $60 million in capital from Kingsbridge over a three-year period through the sale of newly-issued shares of ACADIA’s common stock. The funds that can be raised under the CEFF over the term will depend on the then-current price for ACADIA’s stock and the number of shares actually sold, which may not exceed an aggregate of 7,072,364 shares. ACADIA was required to file the S-3 registration statement to cover the shares issuable pursuant to the CEFF and the up to 350,000 shares that may be exercised pursuant to a warrant, which was issued to Kingsbridge upon the signing of the CEFF. The effectiveness of the S-3 registration statement is a condition to Kingsbridge’s obligation to purchase shares under the CEFF.

ACADIA currently has no specific plans for the CEFF and is not obligated to utilize any of the $60 million available under the CEFF.

San Diego’s branch of the Tech Coast Angels has kicked in $289,000 of a $781,000 Series A financing round for Amplyx Pharmaceuticals Inc., a Menlo Park-based drug development company.

Amplyx’s strategy is to developed improved versions of existing “small molecule” drugs. These drugs are popular because they’re usually orally administered. That’s opposed to drugs made of proteins, such as monoclonal antibodies. These drugs are broken up in the digestive system, so they’re usually given intravenously.

The company’s technology helps these small molecule drugs work better by improving how well they are absorbed, distributed in the body, metabolized and excreted. Called SLF, the technology consists of attaching another small molecule to the drug, a non-toxic molecule that has a long “half life” in the body. The combined new drug is patentable, nice for companies whose drugs have or will soon be going off patent.

“Amplyx has created a unique, simple solution to a huge problem,”  Jack Florio, San Diego TCA member and lead TCA investor in the Amplyx funding, said in a press release announcing the funding. “The company’s platform technology has the potential to improve a large number of drugs, including numerous drugs with billion-dollar markets.”

For more information about Amplyx, listen to this episode of the Frank Peters Show, which documents the activities of angel and venture capital investors.